Secondary Bacterial Infections in Patients With Viral Pneumonia
- PMID: 32850912
- PMCID: PMC7419580
- DOI: 10.3389/fmed.2020.00420
Secondary Bacterial Infections in Patients With Viral Pneumonia
Abstract
Pulmonary diseases of viral origin are often followed by the manifestation of secondary infections, leading to further clinical complications and negative disease outcomes. Thus, research on secondary infections is essential. Here, we review clinical data of secondary bacterial infections developed after the onset of pulmonary viral infections. We review the most recent clinical data and current knowledge of secondary bacterial infections and their treatment in SARS-CoV-2 positive patients; case reports from SARS-CoV, MERS-CoV, SARS-CoV2 and the best-studied respiratory virus, influenza, are described. We outline treatments used or prophylactic measures employed for secondary bacterial infections. This evaluation includes recent clinical reports of pulmonary viral infections, including those by COVID-19, that reference secondary infections. Where data was provided for COVID-19 patients, a mortality rate of 15.2% due to secondary bacterial infections was observed for patients with pneumonia (41 of 268). Most clinicians treated patients with SARS-CoV-2 infections with prophylactic antibiotics (63.7%, n = 1,901), compared to 73.5% (n = 3,072) in all clinical reports of viral pneumonia included in this review. For all cases of viral pneumonia, a mortality rate of 10.9% due to secondary infections was observed (53 of 482). Most commonly, quinolones, cephalosporins and macrolides were administered, but also the glycopeptide vancomycin. Several bacterial pathogens appear to be prevalent as causative agents of secondary infections, including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella pneumoniae.
Keywords: COVID-19; SARS; SARS-CoV-2; antibiotic resistance; influenza; pulmonary viruses; secondary bacterial infection; viral pneumonia.
Copyright © 2020 Manohar, Loh, Nachimuthu, Hua, Welburn and Leptihn.
Figures
Similar articles
-
Bacterial co-infections with SARS-CoV-2.IUBMB Life. 2020 Oct;72(10):2097-2111. doi: 10.1002/iub.2356. Epub 2020 Aug 8. IUBMB Life. 2020. PMID: 32770825 Free PMC article. Review.
-
SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: Secondary bacterial pneumonia and viral co-infections.J Glob Health. 2020 Dec;10(2):020504. doi: 10.7189/jogh.10.020504. J Glob Health. 2020. PMID: 33110587 Free PMC article.
-
Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus.BMC Infect Dis. 2022 Jan 31;22(1):108. doi: 10.1186/s12879-022-07089-9. BMC Infect Dis. 2022. PMID: 35100984 Free PMC article.
-
Comparative incidence of early and late bloodstream and respiratory tract co-infection in patients admitted to ICU with COVID-19 pneumonia versus Influenza A or B pneumonia versus no viral pneumonia: wales multicentre ICU cohort study.Crit Care. 2022 Jun 2;26(1):158. doi: 10.1186/s13054-022-04026-9. Crit Care. 2022. PMID: 35655224 Free PMC article.
-
State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia.Infection. 2021 Aug;49(4):591-605. doi: 10.1007/s15010-021-01602-z. Epub 2021 Mar 11. Infection. 2021. PMID: 33709380 Free PMC article. Review.
Cited by
-
Lung Ultrasound Efficacy in Monitoring Post-SARS-CoV-2 Pneumonia and Inflammatory Biomarkers in Pediatric Patients.Medicina (Kaunas). 2024 Aug 11;60(8):1296. doi: 10.3390/medicina60081296. Medicina (Kaunas). 2024. PMID: 39202577 Free PMC article.
-
Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study.PLoS One. 2022 May 4;17(5):e0267645. doi: 10.1371/journal.pone.0267645. eCollection 2022. PLoS One. 2022. PMID: 35507600 Free PMC article.
-
A pediatric case of fever of unknown origin and pericarditis associated with actinomyces pneumonia.IDCases. 2022 Jul 2;29:e01561. doi: 10.1016/j.idcr.2022.e01561. eCollection 2022. IDCases. 2022. PMID: 35815110 Free PMC article.
-
Pathogenesis of pneumonia and acute lung injury.Clin Sci (Lond). 2022 May 27;136(10):747-769. doi: 10.1042/CS20210879. Clin Sci (Lond). 2022. PMID: 35621124 Free PMC article. Review.
-
The influenza-injured lung microenvironment promotes MRSA virulence, contributing to severe secondary bacterial pneumonia.Cell Rep. 2022 Nov 29;41(9):111721. doi: 10.1016/j.celrep.2022.111721. Cell Rep. 2022. PMID: 36450248 Free PMC article.
References
-
- Mallia P, Footitt J, Sotero R, Jepson A, Contoli M, Trujillo-Torralbo MB, et al. . Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. (2012) 186:1117–24. 10.1164/rccm.201205-0806OC - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous